⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL321045 | 0.73 | — | — | |
| SCHEMBL936459 | 0.61 | — | — | |
| SCHEMBL10103187 | 0.61 | — | — | |
| Methane SCHEMBL21611334 | 0.59 | — | — | |
| SCHEMBL11072942 | 0.58 | — | — | |
| SCHEMBL13819502 | 0.56 | KDM4E (0.33) | — | |
| SCHEMBL14480727 | 0.54 | — | — | |
| SCHEMBL1218300 | 0.54 | — | — | |
| SCHEMBL14040080 | 0.44 | — | — | |
| SCHEMBL7527260 | 0.39 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346752-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2023-11-02 | — | — | US | disclosed |
| US-20230346752-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2023-11-02 | — | — | US | disclosed |
| US-20230331767-A1 | TARGETED STEROID COMPOUNDS | PURDUE RESEARCH FOUNDATION | 2023-10-19 | — | — | US | disclosed |
| US-20230293497-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230293497-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2023-09-21 | — | — | US | disclosed |
| US-11717514-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2023-08-08 | — | — | US | disclosed |
| US-11344623-B2 | Cholecystokinin B receptor targeting for imaging and therapy | PURDUE RESEARCH FOUNDATION (US) | 2022-05-31 | — | — | US | disclosed |
| WO-2022094609-A1 | OLIGONUCLEOTIDE-BASED THERAPEUTICS AND USES THEREOF | SPEER TOD (US) | 2022-05-05 | — | — | WO | disclosed |
| US-11318121-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2022-05-03 | — | — | US | disclosed |
| US-11219622-B2 | Folate receptor binding conjugates of antifolates | ENDOCYTE, INC. (US) | 2022-01-11 | — | — | US | disclosed |
| WO-2008112873-A2 | BINDING LIGAND LINKED DRUG DELIVERY CONJUGATES OF TUBULYSINS | ENDOCYTE, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
| US-20080152702-A1 | Releasable linkage and compositions containing same | ZALIPSKY SAMUEL | 2008-06-26 | — | — | US | disclosed |
| US-7390780-B2 | Gene delivery mediated by liposome-DNA complex with cleavable peg surface modification | ALZA CORPORATION (US) | 2008-06-24 | — | — | US | disclosed |
| EP-1880736-A1 | Releasable linkage and composition containing same | Alza Corporation (US) | 2008-01-23 | — | — | EP | disclosed |
| US-7303760-B2 | Method for treating multi-drug resistant tumors | ALZA CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-7285622-B2 | Releasable linkage and compositions containing same | ALZA CORPORATION (US) | 2007-10-23 | — | — | US | disclosed |
| US-7276248-B2 | Conjugate having a cleavable linkage for use in a liposome | ALZA CORPORATION (US) | 2007-10-02 | — | — | US | disclosed |
| US-7238368-B2 | Releasable linkage and compositions containing same | ALZA CORPORATION (US) | 2007-07-03 | — | — | US | disclosed |
| WO-2007022494-A2 | MULTI-DRUG LIGAND CONJUGATES | ENDOCYTE, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| WO-2007022493-A2 | LIGAND CONJUGATES OF VINCA ALKALOIDS, ANALOGS, AND DERIVATIVES | ENDOCYTE, INC. (US) | 2007-02-22 | — | — | WO | disclosed |